<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Access to life-saving medicines in Europe (debate) - Tuesday, 16 September 2014</title><meta name="title" content="Verbatim report of proceedings - Access to life-saving medicines in Europe (debate) - Tuesday, 16 September 2014" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2014 - Source: European Parliament" /><meta name="available" content="16-09-2014" /><meta name="sipade-leg" content="8" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Access to life-saving medicines in Europe (debate) - Tuesday, 16 September 2014" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-8-2014-09-16-ITM-019_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-8-2014-09-16-ITM-019_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2014-09-16-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2014-09-16-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2014-09-16-ITM-018_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2014-09-16-ITM-018_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-8-2014-09-16-ITM-020_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-8-2014-09-16-ITM-020_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2014-09-16_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2014-09-16_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table><table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Tuesday, 16 September 2014 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 19. Access to life-saving medicines in Europe (debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:04:07&amp;playerEndTime=20140916-22:37:02" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:04:07&amp;playerEndTime=20140916-22:37:02" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:04:07&amp;playerEndTime=20140916-22:37:02" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-8-2014-09-16-ITM-019_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-8-2014-09-16-ITM-019_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-8-2014-09-16-ITM-019_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="2-444-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2323.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:04:07&amp;playerEndTime=20140916-22:04:17" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Der Präsident. -</span></span>   Als nächster Punkt der Tagesordnung folgt die Aussprache über die Erklärung der Kommission zum Zugang zu lebensrettenden Arzneimitteln in Europa (<a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2014/2831(RSP)">2014/2831(RSP)</a>).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-445-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:04:17&amp;playerEndTime=20140916-22:07:58" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Connie Hedegaard, </span></span>  <span class="italic">Member of the Commission</span><span class="bold">. -</span> Mr President, on behalf of my colleague Commissioner Borg, I would like to think that the Commission shares the general concern regarding the affordability of new medical products and the related risk of inequalities arising in access to care. </p>
<p class="contents">The Commission is committed to helping Member States respond to this challenge. This commitment was highlighted in the Commission’s communication of April this year on effective and resilient health systems, which, among other things, focused on increasing accessibility to health systems. The communication stressed the need for improved cooperation, ‘increased transparency and better coordination to minimise any unintended effects that current national pricing systems may have in terms of accessibility throughout the EU’.</p>
<p class="contents">At the Health Council in June, the French delegation raised the specific issue of the new improved hepatitis C treatments which have recently received marketing authorisation in the European Union, expressing concerns in relation to achieving equitable access to these treatments. Tomorrow Member States’ experts will meet to discuss the new improved hepatitis C treatments. There will be a follow-up meeting with Member States’ competent authorities next month to discuss pricing and reimbursement.</p>
<p class="contents">Of course, the discussion on the impact of prices on the affordability of medicines for public payers and patients goes far beyond the specific case of hepatitis C treatments. The Commission is therefore looking forward to the debate planned by the Italian Presidency on therapeutic innovation at next week’s informal Council of Health Ministers. The outcome of this debate will help inform the new Commission about the interest of Member States in continuing an EU debate on the affordability of innovative health products.</p>
<p class="contents">As regards support to research and development, the Commission is hopeful that the ongoing Innovative Medicines Initiative will help speed up the development of better and safer medicines. EU pharmaceutical legislation contains a number of tools to facilitate early access to medicines for patients with unmet medical needs. In addition, in terms of success in helping the development and the placing on the market of medicines for rare and life-threatening diseases, the Commission has already authorised 106 of such innovative treatments.</p>
<p class="contents">The Commission has, however, no competence to regulate the level of prices of medicinal treatments. These are determined by Member States individually. Thus there can be no price caps imposed by the Commission. However, the Commission can offer help, for example, by pursuing improved exchanges of information among Member States on their pricing policies with a view to minimising negative effects on the accessibility of medicines in the EU. Another way in which the Commission could assist would be by further exploring the use of the joint procurement mechanism to obtain more advantageous price offers from the pharmaceutical industry.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-446-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28178.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:08:08&amp;playerEndTime=20140916-22:10:47" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Mikolášik, </span></span>  <span class="italic">za skupinu PPE</span><span class="bold">. – </span>Táto debata na pléne v Štrasburgu v túto neskorú večernú hodinu by nás mala vyburcovať ku kvalitnej diskusii, ale predovšetkým ku hmatateľným výsledkom. Dnes nám ide o človeka, o pacienta, ktorý veľmi naliehavo potrebuje svoje lieky. Prístup k život zachraňujúcim liekom, to je predsa téma dnešnej debaty.</p>
<p class="contents">Osud miliónov pacientov, či už na Slovensku, Fínsku, Írsku, Taliansku, kdekoľvek, mi leží na srdci nielen preto, že som ako lekár videl aj zomierať ľudí a viem zo svojej bývalej lekárskej praxe na život zachraňujúcom oddelení nemocnice, aké dôležité je mať potrebné kvalitné lieky k dispozícii a nielen na reanimačnej jednotke, ale aj na všetkých nemocničných oddeleniach a hlavne, aby pacient s vážnym ochorením mal skutočný, reálny prístup ku liekom. Ku liekom, ktoré sú a budú cenovo prístupné, v jeho sociálnej situácii a príjmovej hladine a budú zároveň kvalitné a plne dostupné.</p>
<p class="contents">Stále existuje nerovnosť v prístupe k potrebným liekom, čo je čiastočne zapríčinené aj rôznou úrovňou financovania zdravotníctva v rôznych členských krajinách, čo sa potom premieta do ceny liekov, do rôznej ceny, i neustáleho nárastu farmaceutických výdavkov a pretrváva vysoká cena liekov čiastočne aj preto, že nové technológie sú finančne náročné. Na druhej strane farmaceutické firmy, ktoré nové liečivo vyvinú, by nemali zneužívať svoju exkluzívnu pozíciu a vyháňať potom cenu liekov do neúnosných hladín. Je to neetické a nemorálne.</p>
<p class="contents">V rokoch 2000 až 2009 totiž narástli v krajinách EÚ verejné výdavky na lieky v priemere až o 76 %. Tieto výdavky na lieky rastú rýchlejšie než HDP členských štátov. A treba si zároveň uvedomiť, že je starnúca populácia v členských štátoch, inými slovami je viacej dôchodcov a stále sa vzďaľujúca cena novovyvíjaných liekov. V tejto súvislosti treba systémovo dovoliť, aby rovnaká molekula v oblasti generík mohla byť čo najskôr a za nepomerne nižšiu cenu pacientom k dispozícii.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-447-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:10:56&amp;playerEndTime=20140916-22:12:31" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Biljana Borzan, </span></span>  <span class="italic">u ime kluba S&amp;D</span><span class="bold">. –</span> Gospodine predsjedniče, s napretkom medicinske znanosti pojavljuju se iznimno učinkoviti i skupi lijekovi. Kada se na tržištu pojavi lijek koji osigurava 100 % izlječenje, sigurna sam da nema liječnika koji želi birati između dobrobiti pacijenta i uštede u zdravstvenom proračunu. Ukoliko govorimo o cijeni zdravstva, u ovom slučaju skupog lijeka koji u potpunosti liječi hepatitis, postavljam pitanje: koliko društvo koštaju sve hospitalizacije koje će bez izlječenja taj čovjek doživjeti, sva dijagnostika, koliko košta sva terapija, izostanci s posla i naravno ono najvažnije koliko košta ljudski život?</p>
<p class="contents">Smeta mi kada se milijarde eura troše na spašavanje banaka, a kada je lijek u pitanju svi su zabrinuti za troškove. No, s druge sam strane svjesna da moramo odgovorno razmišljati o održivom zdravstvenom sustavu. Stoga je jedno od mogućih rješenja, kada su skupi lijekovi u pitanju, da se iz javnih sredstava farmaceutskim tvrtkama plaća samo kada dođe do izlječenja. </p>
<p class="contents">Nadalje, postoji mogućnost da se skrati trajanje prava na patent jer kada ono istekne cijena lijeka rapidno pada. Nakon svega, moram izraziti razočaranje što će lijekovi i medicinski proizvodi u budućoj Komisiji biti pod povjerenikom za industriju i poduzetništvo, umjesto pod povjerenikom za zdravlje. To je korak unatrag i nažalost signal da sigurnost pacijenata gubi primat pred ekonomskom računicom. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-448-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124825.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:12:41&amp;playerEndTime=20140916-22:14:26" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Beatrix von Storch, </span></span>  <span class="italic">im Namen der ECR-Fraktion</span><span class="bold">. –</span> Herr Präsident! Wir sind alle für den Schutz menschlichen Lebens und deswegen auch für die weitestgehende Verbreitung und den Zugang zu lebenserhaltenden Medikamenten.</p>
<p class="contents">Hinsichtlich der Erforschung dieser Medikamente möchte ich einen Punkt machen mit Blick auf die Verwendung embryonaler Stammzellen: Der Europäische Gerichtshof hat am 18. Oktober 2011 eine sehr wichtige Grundsatzentscheidung getroffen. Der EuGH hat festgestellt, dass das menschliche Leben beginnt zu existieren mit der Verschmelzung von Ei und Samenzelle. Der Mensch ist ab der Verschmelzung von Ei und Samenzelle ein Mensch.</p>
<p class="contents">Nach dieser Rechtsprechung müssten alle öffentlichen Mittel für jedweden Eingriff in dieses frühe Leben, jede Manipulierung und erst recht jede Vernichtung gestrichen werden. Embryonale Stammzellenforschung ist damit unzulässig, und genau das hat die Europäische Bürgerinitiative Einer von uns (<span class="italic">One of us</span>) gefordert. 1,8 Millionen Unionsbürger haben diese Initiative unterstützt. </p>
<p class="contents">Die von den Christdemokraten geführte EU-Kommission hat es trotz dieser 1,8 Millionen Unterschriften abgelehnt, zu dieser Problematik überhaupt nur Stellung zu nehmen, geschweige denn irgendwelche Maßnahmen gegen die Vernichtung von menschlichem Leben für Forschungszwecke zu ergreifen. </p>
<p class="contents">Wenn wir über die Herstellung von Medikamenten sprechen, sollten wir bedenken: Schützen wir das menschliche Leben durch die Verbreitung lebenserhaltender Medikamente, und stoppen wir die Vernichtung menschlichen Lebens für Forschungszwecke!</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-449-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125040.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:14:35&amp;playerEndTime=20140916-22:16:46" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Beatriz Becerra Basterrechea, </span></span>  <span class="italic">en nombre del Grupo ALDE</span><span class="bold">. –</span> Señor Presidente, Señora Hedegaard, he escuchado con tanto interés como expectación la declaración de la Comisión sobre el acceso a medicamentos que salvan vidas.</p>
<p class="contents">Permítanme utilizar este espacio de debate y responsabilidad que es el Parlamento Europeo para traer a primer plano la prioridad irrenunciable de nuestro trabajo, que es servir al interés general.</p>
<p class="contents">¿Qué naturaleza epidémica ha de adquirir una patología para ser considerada «crisis de salud pública»? ¿Son suficientes los 130 millones de enfermos de hepatitis C en el mundo, 10 millones de ellos en la Unión Europea, casi 1 millón solo en España? </p>
<p class="contents">La hepatitis C es una enfermedad infecciosa que, cuando se cronifica, se convierte en incapacitante y devastadora. Es mortal en medio millón de casos al año. Pero ahora existe una cura. Y esa cura tiene un precio. Un precio inasumible de más de 50 000 euros por paciente y tratamiento, fijado por la compañía propietaria de la patente del sofosbuvir, atendiendo exclusivamente a criterios de mercado.</p>
<p class="contents">¿Vamos a resignarnos, de nuevo, a dar excusas que justifiquen la parálisis institucional europea? ¿Vamos a limitarnos a lamentar la fatalidad del lucro corporativo?</p>
<p class="contents">Yo creo que no, Señorías. Yo creo que podemos actuar y que existen las herramientas. Los Estados miembros pueden aplicar el artículo 31 de la Declaración de Doha de 2001, promovida por la Organización Mundial del Comercio; pueden emitir una licencia obligatoria por «necesidad de salud pública» y fabricar un genérico. También pueden oponerse legalmente a la patente, como ya ha hecho la India, ya que la molécula fue patentada previamente contra el cáncer. O pueden negociar el pago conjunto de cesión de la patente. O, cómo no, optar por formar un bloque y realizar compras públicas agregadas. Egipto importa hoy el genérico indio del sofosbuvir a un precio 100 veces menor. Otros 90 países en desarrollo se beneficiarán también de la decisión de la India.</p>
<p class="contents">¿Pueden comprometerse la Comisión y este Pleno a promover una posición común para defender el interés general y el cumplimiento de los Tratados?</p>
<p class="contents">Si hemos sido capaces en Europa de imponer límites al <span class="italic">roaming</span>, ¿no vamos a ser capaces de cambiar el modelo de fijación de precios de los medicamentos que salvan millones de vidas?</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-450-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125061.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:16:54&amp;playerEndTime=20140916-22:18:06" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Κώστας Χρυσόγονος, </span></span>  <span class="italic">εξ ονόματος της ομάδας GUE/NGL</span><span class="bold">. –</span> Κύριε Πρόεδρε, το πρόβλημα της υπερκοστολόγησης των φαρμάκων από τις φαρμακευτικές εταιρείες, οι οποίες σκοπό έχουν να αποκομίσουν υπερκέρδη σε βάρος της υγείας των πολιτών και σε βάρος των ασφαλιστικών ταμείων, είναι υπαρκτό. Αλλά δεν είναι το μόνο εμπόδιο όσον αφορά την πρόσβαση στις αναγκαίες φαρμακευτικές αγωγές. Στην πραγματικότητα, τα αρμόδια όργανα της Ευρωπαϊκής Ένωσης, όχι μόνο αδιαφορούν για τις υπερκοστολογήσεις, αλλά και προωθούν συνειδητά πολιτικές περιορισμών στις δημόσιες δαπάνες για την υγεία που δυσκολεύουν ακόμη περισσότερο την πρόσβαση των ασθενών στα φάρμακα.</p>
<p class="contents">Στην χειρότερη κατάσταση από όλους, βρίσκονται οι χώρες κάτω από καθεστώς μνημονίου, όπου η Τρόικα ακολουθεί πολιτικές βίαιης φτωχοποίησης, με αποτέλεσμα οι ασθενείς να αδυνατούν να καταβάλουν τη συμμετοχή τους στη φαρμακευτική δαπάνη και να αυξάνεται η θνησιμότητα. Στην Ελλάδα, οι θάνατοι από 108 000 το 2009, αυξήθηκαν στις 117 000 το 2012, ως αποτέλεσμα, ακριβώς, αυτής της εγκληματικής πολιτικής της Τρόικας. Η Ευρωπαϊκή Επιτροπή ...</p>
<p class="contents"><span class="italic">(Ο Πρόεδρος διακόπτει τον ομιλητή.)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-451-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96743.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:18:14&amp;playerEndTime=20140916-22:20:26" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Michèle Rivasi, </span></span>  <span class="italic">au nom du groupe Verts/ALE</span><span class="bold">. – </span>Monsieur le Président, nous sommes quand même dans une situation assez grave. J'ai écouté vos propositions mais je les trouve un peu faibles. Nous avons appris que quinze États ont saisi la Commission au sujet de ce médicament contre l'hépatite C qui est le sofosbuvir. Il faut quand même savoir que son coût est de l'ordre de 50 000 à 60 000 euros par patient pour une durée de douze semaines. C'est donc énorme par rapport au budget. Et cela touche huit millions de personnes au niveau de l'Europe. </p>
<p class="contents">En même temps, si cela ne concernait que ce laboratoire pharmaceutique qui sort ce médicament, mais cela concerne maintenant énormément de médicaments pour soigner le cancer du sein, le cancer du rein. Beaucoup d'États jouent désormais au rationnement, c'est-à-dire sur le coût-bénéfice: si vous êtes trop âgé, vous n'y avez plus droit car le budget de la sécurité sociale ne pourra pas y répondre. Donc, c'est vraiment un problème de santé publique.</p>
<p class="contents">Alors pourquoi en sommes-nous arrivés là? Certains l'ont dit tout à l'heure: c'est un problème du monopole et du brevet. Si ces brevets sont sur vingt ans et que les États ont trop souvent joué sur le monopole, il y a une sortie de secours qui est la licence obligatoire. Il faut dire aux États d'utiliser cette licence parce que cela permet d'ouvrir le marché et d'autres laboratoires peuvent très bien fabriquer des médicaments beaucoup moins chers.</p>
<p class="contents">Se pose a aussi le problème de la recherche. Regardez le cas Ebola, la crise qu'il y a à l'heure actuelle en Afrique de l'Ouest. Cela fait depuis 1976 que nous connaissons ce virus Ebola, mais aucun laboratoire pharmaceutique ne veut faire des vaccins et des traitements parce que ce n'est pas rentable! Autrement dit, nous sommes sur une politique de marché.</p>
<p class="contents">Or, à partir du moment où nous mettons de l'argent public, où la Commission européenne met de l'argent public, il faut absolument une conditionnalité pour qu'il n'y ait pas de monopole et pas de brevets. Cela permet d'avoir des prix de médicaments beaucoup moins chers et ainsi d'assurer l'accès aux médicaments et de contribuer aussi à l'innovation parce que nous sommes en déficit d'innovation. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-452-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124813.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:20:31&amp;playerEndTime=20140916-22:21:39" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dario Tamburrano, </span></span>  <span class="italic">a nome del gruppo EFDD</span><span class="bold">. –</span> Signor Presidente, onorevoli colleghi, accolgo con grande piacere questo dibattito, sia perché sono un dentista e conosco i drammi dell'epatite C sia perché in generale noi del Movimento 5 Stelle crediamo che i principi etici, cui si dovrebbe ispirare il mondo della farmaceutica dovrebbero vincere sempre sulle logiche di mercato.</p>
<p class="contents">I nuovi portafogli della Commissione prevedono più competenze sui farmaci per il Commissario all'industria, mentre in ogni paese membro ne è responsabile il ministro della Salute. Come pensiamo di fare gli interessi dei cittadini quando sarà la DG Industria ad avere competenza in questa materia piuttosto che l'Istituzione europea a tutela della salute pubblica? Com'è possibile che in questo Parlamento per giunta a maggioranza cattolica, dove risuonano spesso richiami ai valori del rispetto e della salvaguardia della vita, non si agisca fortemente per ridurre i costi dei farmaci indispensabili?</p>
<p class="contents">Proprio oggi una serie di ONG del settore ha scritto allarmata in tal senso: "Non è forse la vita di noi cittadini ad essere il valore prioritario da difendere?" </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-453-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125109.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:21:48&amp;playerEndTime=20140916-22:22:52" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Εύα Καϊλή (S&amp;D). -</span></span>   Κυρία Επίτροπε, καταλαβαίνω πως μας θέσατε τα αδιέξοδα για τη ρύθμιση των τιμών των διπλωμάτων ευρεσιτεχνίας στα φάρμακα και θα προσπαθήσω να βρω τρόπους να σας διευκολύνω για άλλες λύσεις, καθώς η συμφωνία TRIPS επιτρέπει, σε περιπτώσεις φαρμάκων, την αδειοδότηση των γενοσήμων. Εκεί λοιπόν που τα ανθρώπινα δικαιώματα υπερέχουν των πνευματικών δικαιωμάτων - και, αναρωτιέμαι, ενεργοποιήθηκε κατά περίπτωση η Γερμανία και η Ιταλία - γιατί δεν ελέγχεται τουλάχιστον με υποχρεωτική διαφάνεια το πραγματικό κόστος των ερευνών που διεξάγουν οι πολυεθνικές εταιρείες και, στη συνέχεια, σε περιπτώσεις αισχροκέρδειας, να λήγει σε λιγότερο από 20 χρόνια η ισχύς των διπλωμάτων ευρεσιτεχνίας για τα φάρμακα, ή να εξορθολογίζονται οι τιμές τους;</p>
<p class="contents">Η Ευρωπαϊκή Ένωση θα μπορούσε να αρνείται, σε συνεννόηση φυσικά με τα κράτη μέλη μέσω των δημοσίων συστημάτων υγείας τους, να παραλαμβάνει και να αγοράζει σε εξωφρενικά ακριβές τιμές αυτά τα φάρμακα. Θα μπορούσε λοιπόν, στις περιπτώσεις αισχροκέρδειας ή σε περιπτώσεις που υπάρχει μεγάλη ανάγκη για την υγεία των ανθρώπων, να αδειοδοτεί γενόσημα.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-454-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124927.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:22:57&amp;playerEndTime=20140916-22:25:13" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Branislav Škripek (ECR). - </span></span>  Je pravda, že vývoj nových liekov na záchranu života je finančne veľmi náročný. Nie je však obhájiteľné, aby pacient nemal zaistenú potrebnú starostlivosť z finančných dôvodov. Každý pacient v Európe má právo na kvalitnú liečbu a dostupnosť liekov. </p>
<p class="contents">Tu je nutné nekompromisne uplatňovať zásadu spravodlivého prerozdeľovania prostriedkov. Je neakceptovateľné, aby takéto lieky boli dostupné len privilegovaným a sociálne slabší boli z takej liečby vylúčení. Potom nastávajú situácie, keď sa otvárajú dvere korupcie a klientelizmu, proti čomu chceme v Európe bojovať. </p>
<p class="contents">Ak hovoríme o liekoch na záchranu života, mali by sme tu zároveň hovoriť o situáciách, keď sú možnosti aktívneho a zásadného ovplyvnenia prognózy ochorenia vyčerpané. Tu by mala nastúpiť paliatívna starostlivosť. V kontraste s bežnými liečebnými postupmi, táto ponúka vyššiu kvalitu života i v prípadoch pokročilých chorôb a v terminálnych štádiách. Ide o starostlivosť, ktorá s plným rešpektom dôstojnosti a právam človeka zaisťuje ťažko chorým alebo ľuďom na sklonku života kvalitnú a komplexnú starostlivosť. </p>
<p class="contents">Predpokladám, že väčšina politikov pozná výrok: „Civilizácia je natoľko vyspelá, nakoľko sa stará o svojich najslabších a nemohúcich členov.“ Podľa mňa je práve na zodpovednosti politikov, aby sme pri svojej práci tento výrok napĺňali. Je šokujúce, že naša vyspelá civilizácia namiesto snahy uľahčiť starým a smrteľne chorým zaistenie osobitnej starostlivosti, čím ďalej usiluje o ich odstránenie. V minulosti boli zatváraní do ústavov, dnes je pre nich presadzované finančne nenáročné riešenie, totiž eutanázia. </p>
<p class="contents">Paradox. Vyspelosť a blahobyt Európy nám umožňuje skutočné kvalitné a dôstojné dožitie pre každého, ale my stále diskutujeme a ospravedlňujeme, ako sa nerentabilných ľudí zbavíme. Posledným strašným príkladom je Belgicko, kde rozšírili eutanáziu na deti a psychicky chorých. </p>
<p class="contents">Neviem si pomôcť, ale pripomína mi to starovekú Spartu, kde zabíjali nevhodné deti, či nacistickú eugeniku, kde odstraňovali nevyhovujúcich. K čomu takýto náhľad vedie? Spoločnosť sa začne zbavovať ľudí s postihnutím alebo takých, ktorí nevyhovujú našim štandardom. Musím konštatovať, že u nás na Slovensku nie je paliatívnej starostlivosti zo strany štátu venovaná náležitá<span class="italic">….(rečník bol prerušený)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-455-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28116.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:25:19&amp;playerEndTime=20140916-22:27:03" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marian Harkin (ALDE). -</span></span>   Mr President, in the context of access to life-saving medicines in Europe, shortages are caused by a number of factors. They are caused by supply issues, they are caused by production issues and, most certainly, they are caused by affordability issues. I intend to concentrate on the affordability issues.</p>
<p class="contents">The problem is particularly acute in countries undergoing austerity programmes, largely because of the cuts to public services across the board, which of course limit access to healthcare and life-saving medicines. The Commission itself, in its country-specific recommendations, tells us that limitations on access to healthcare may weigh disproportionately on the more vulnerable sections of society, the people who rely disproportionately on public services. In my own country, Ireland, the cuts in health expenditure between 2009 and 2011 were of the order of 17% and, according to Social Justice Ireland, the cuts in 2013 amounted to 5%. That comes to more than one-fifth of the healthcare budget, and the impact on access to healthcare and life-saving medicines has been huge.</p>
<p class="contents">Lastly, I want to add my voice to the long list of organisations, including the European consumer organisation AGE Platform, and the Standing Committee of European Doctors, asking Commissioner Juncker to revisit his decision to move medicinal products and health technologies into the portfolio of the Commissioner for the Internal Market. That Commissioner’s mandate, of course, is to promote the competitiveness of the industry, whereas the main driver of EU policies on medicine and health technologies should be the promotion of health and patient safety.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-456-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96820.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:27:10&amp;playerEndTime=20140916-22:28:22" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marisa Matias (GUE/NGL). -</span></span>   Senhor Presidente, haver uma farmacêutica que cobra 60 000 euros ou 50 000 euros pelo tratamento de um doente de hepatite C por três meses é uma vergonha. Em Portugal, se se fosse a aplicar este medicamento para todos os doentes de hepatite C, significaria pagar por este medicamento o equivalente aos custos da totalidade dos medicamentos agora gastos nos hospitais. </p>
<p class="contents">O que nós sabemos é que as patentes e o monopólio das patentes, a par da austeridade, estão a matar completamente os sistemas de saúde. E não é por uma questão de inovação, porque apenas 10 % do custo que é pago pelo medicamento é dedicado à investigação. Não é de inovação que se trata, é mesmo de lucro, lucro vergonhoso. Se estes 10 % fossem investidos na investigação, escusavam os Estados e os contribuintes de pagar os 90 % de lucro. </p>
<p class="contents">A Comissão diz que não pode fazer nada relativamente a isto, relativamente aos preços. Poderá não fazer relativamente aos preços, mas pode fazer relativamente às patentes. Pode ajudar a acabar com estes monopólios, que estão a ser pagos pelos Estados. Pode ajudar a acabar com os monopólios, assim haja vontade política.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-457-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28161.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:28:25&amp;playerEndTime=20140916-22:29:35" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Margrete Auken (Verts/ALE). - </span></span>  Hr. Formand! Denne debat viser, at vi er nødt til at gøre noget, hvis medicinalindustriens grådighed og kynisme er fuldstændig grænseløse. Og vi kan gøre noget! Jeg tror, Kommissionen er opmærksom på, at op imod 50 % af forsknings-/udviklingsomkostningerne betales af det offentlige, hvorefter vi lader industrien udplyndre os. Det er præcis dér, vi skal tage fat nu. Vi skal selvfølgelig ikke flytte medicinalindustrien over til GD for Erhvervspolitik. Det er en meget, meget kynisk idé. Men vi skal derudover for alvor nu kigge på hele den måde, dette er strikket sammen på. Vi udplyndrer landene, vi lader folk dø, og vi kan godt reagere. Det, der mangler her, er en lille bitte smule indsigt, og så er det noget politisk vilje. Som økonomen Mariana Mazzucato sagde: "Vi har med dette system socialiseret risiciene og privatiseret profitten". Vi bør altså gøre det modsatte. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-458-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125112.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:29:43&amp;playerEndTime=20140916-22:31:00" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Γιώργος Γραμματικάκης (S&amp;D). -</span></span>   Κύριε Πρόεδρε, τα τελευταία χρόνια έχουν παρατηρηθεί σημαντικές ελλείψεις φαρμάκων στην Ελλάδα. Εκεί οδήγησε ένα εκρηκτικό μείγμα παραγόντων, άμεσα σχετιζομένων με την οικονομική κρίση και τα σκληρά και παράλογα μνημόνια που έχουν επιβληθεί στη χώρα. Στο πλαίσιο εξορθολογισμού της φαρμακευτικής δαπάνης, οι τιμές των φαρμάκων μειώθηκαν αισθητά. Δημιούργησαν όμως παράλληλα σημαντικές παρενέργειες. Διάφορες φαρμακοβιομηχανίες μείωσαν τις ποσότητες εισαγωγών ή και τις σταμάτησαν ολοκληρωτικά. Οι παράλληλες εξαγωγές φαρμάκων σε χώρες της Ευρωπαϊκής Ένωσης όπου οι τιμές είναι υψηλότερες, ανάγκασαν τον Εθνικό Οργανισμό Φαρμάκων να προχωρήσει σε μια σειρά απαγορεύσεων. </p>
<p class="contents">Μια μικρή χώρα όπως η Ελλάδα δεν έχει τα μέσα να αντισταθεί στην παύση ή στη μείωση εισαγωγών των φαρμακοβιομηχανιών. Είναι λοιπόν απαραίτητο ένα νέο ευρωπαϊκό πλαίσιο που θα θεσπίσει την υποχρέωση των εταιρειών να παρέχουν τα προϊόντα τους και στις χώρες που αντιμετωπίζουν οικονομικές δυσκολίες. Όταν απειλείται η υγεία συμπολιτών μας δεν χωρούν καθυστερήσεις που ...</p>
<p class="contents"><span class="italic">(Ο Πρόεδρος διακόπτει τον ομιλητή.)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-459-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125050.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:31:08&amp;playerEndTime=20140916-22:32:23" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ángela Vallina (GUE/NGL). -</span></span>   Señor Presidente, en Europa y en los Estados Unidos los medicamentos son la tercera causa de muerte, tras el cáncer y las enfermedades del corazón: es evidente que hace falta un mayor control de los fármacos comercializados.</p>
<p class="contents">Unos 170 millones de personas tienen hepatitis C en el mundo y unas 800 000 personas en España; el tratamiento convencional consigue alrededor de un 70 % de curaciones, pero tiene un elevado número de efectos adversos graves, por lo que muchos pacientes no pueden iniciarlo.</p>
<p class="contents">Recientemente han aparecido nuevos fármacos que consiguen curar a la gran mayoría de los enfermos tratados, un 95 %, sin efectos secundarios importantes, pero su precio es extraordinariamente elevado, lo cual hace inaccesible la adquisición individual para la mayoría de las personas que lo necesitan y lo hace difícilmente asumible para los sistemas sanitarios públicos, dado que hay que tratar a decenas de personas.</p>
<p class="contents">Es inaceptable el establecimiento de precios tan elevados para medicamentos tan necesarios. Reclamamos una disminución en el precio de estos medicamentos que haga posible el tratamiento. No podemos ser testigos silenciosos del deterioro progresivo y la muerte de estos enfermos cuando hay tratamientos eficaces y seguros.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-460-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125041.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:32:34&amp;playerEndTime=20140916-22:33:46" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Soledad Cabezón Ruiz (S&amp;D). -</span></span>   Señor Presidente, la Agencia Europea de Medicamentos aprobó hace unos meses el sofosbuvir, que erradica la hepatitis C en el 90 % de los casos, y cuyo coste es de al menos 60 000 euros por tratamiento.</p>
<p class="contents">Lo primero que debería hacer la Agencia Europea de Medicamentos es investigar un posible caso de abuso, sobre todo cuando la propia empresa que lo fabrica negocia con empresas de la India para vender su tecnología para producir genéricos con un coste de 1 400 euros.</p>
<p class="contents">Por otro lado, es ya hora de que, por fin, se desbloquee la necesaria reforma de la Directiva de 1988 sobre la transparencia en la fijación de precios de los medicamentos y su reembolso, y se tomen medidas que garanticen la sostenibilidad de los diferentes sistemas sanitarios nacionales.</p>
<p class="contents">Señorías, el poder adquisitivo no puede ser discriminatorio para el acceso a los medicamentos que salvan vidas, como es este el caso o el de los anticancerígenos. La sanidad no es competencia de la Unión Europea, pero sí lo es el mercado interior, la competencia o los derechos de propiedad intelectual y la investigación. Por lo tanto, no permitamos que con la salud se mercadee.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-461-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:33:45&amp;playerEndTime=20140916-22:34:07" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">Catch-the-eye-Verfahren</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-462-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:34:06&amp;playerEndTime=20140916-22:35:17" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">João Ferreira (GUE/NGL). -</span></span>   Senhor Presidente, a Comissão vem aqui hoje fazer-nos uma declaração sobre o acesso a medicamentos vitais na Europa. O tema presta-se, naturalmente, a declarações pias e bondosas, e a Comissão diz estar preocupada com os custos e a dificuldade de acesso a vários medicamentos e, pasme-se, com a desigualdade nesse acesso, e quer ajudar os Estados-Membros nesta matéria. A Comissão Europeia, a mesma Comissão que faz parte da troica, a mesma troica que, por exemplo, em Portugal, e de forma ilegítima, impôs o aumento do preço dos medicamentos e a redução das comparticipações do Estado, o que teve como resultado graves limitações no acesso aos medicamentos. </p>
<p class="contents">Muitos utentes, em especial os mais idosos e os de mais baixos rendimentos, têm hoje uma opção: ou os medicamentos na farmácia ou os alimentos. Alguns hospitais deixaram de disponibilizar medicamentos aos utentes nas farmácias hospitalares. Costuma-se dizer: muito ajuda quem não atrapalha. Os Estados-Membros são responsáveis pela organização dos serviços de saúde, pelos sistemas de saúde e pelos recursos que lhes são afetados. É necessário afrontar as transnacionais do medicamento, mas não podemos contar com esta Comissão Europeia para o fazer...</p>
<p class="contents"><span class="italic">(O Presidente retira a palavra ao orador)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-463-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:35:17&amp;playerEndTime=20140916-22:35:31" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">(Ende des Catch-the-eye-Verfahrens)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-464-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:35:30&amp;playerEndTime=20140916-22:36:52" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Connie Hedegaard, </span></span>  <span class="italic">Member of the Commission</span><span class="bold">. -</span> Mr President, you will understand why, at this late hour, I will not go into much detail on what you have been saying. Needless to say, the sense of what you have suggested and reflected on here tonight will be conveyed to Commissioner Borg, who is responsible for this portfolio. He will also have people from his team who are listening to this debate and taking notes.</p>
<p class="contents">As early as tomorrow, experts from the working group and from the Member States will meet and discuss this, so that could be one opportunity for Member States to try to continue this debate and take it forward. However, I have to say to Mr Ferreira, who in his closing remarks here talked about the pricing of medicine: I am sorry, but I have to restate that the pricing of medicine is not within EU competence. That does not mean that there is nothing we can do at EU level; there are other things, for instance, the exchange of information. There are other things, and as far as I understand it, the informal Health Council will actually have this on their agenda at their next meeting. Thank you very much for the input. As I said, it will be conveyed to Commissioner Borg, who is responsible for this area.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-465-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2323.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20140916-22:36:49&amp;playerEndTime=20140916-22:37:01" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Der Präsident. -</span></span>   Die Aussprache ist geschlossen.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
